This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, L. D. Articles by Mullen, C. A. Search for Related Content PubMed PubMed Citation Articles by Anderson, L. D., Jr. Articles by Mullen, C. A.

Enhancement of Graft-Versus-Tumor Activity and Graft-Versus-Host Disease by Pretransplant Immunization of Allogeneic Bone Marrow Donors with a Recipient-derived Tumor Cell Vaccine¹

Departments of Experimental Pediatrics [L. D. A., D. P., L. A. E., C. A. M.] and Immunology [C. A. M.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Allogeneic bone marrow transplantation (BMT) can be accompanied by a beneficial T cell-mediated antitumor immune response known as graft-versus-tumor (GVT) activity. However, BMT donor T cells are not exposed to target antigens of GVT activity until transfer to the host, where tumor antigen presentation may be suboptimal. This study tested in a murine model the hypothesis that immunization of MHC-matched allogeneic donors with a recipient-derived tumor cell vaccine would substantially increase GVT activity and extend survival of BMT recipients with preexisting micrometastatic tumor.

C3H.SW and C57BL/10 mice were immunized against a C57BL/6-derived fibrosarcoma or leukemia, and they were used as BMT donors. Recipients were H-2-matched, minor histocompatibility antigen-mismatched C57BL/6 mice with previously established micrometastatic tumors. Donor immunization led to a significant increase in GVT activity that was T cell dependent and cell dose dependent. In some settings, donor immunization also prolonged survival of recipients with preexisting micrometastatic tumors. However, donor immunization significantly increased the incidence of fatal graft-versus-host disease such that long-term survival was uncommon. In vitro cytotoxicity assays indicated that donor immunization induced both tumor-selective and alloreactive cytolytic T-cell populations. In vivo cross-protection assays showed that a substantial portion of the GVT effect was mediated by alloreactive cells not specific for the immunizing tumor. In conclusion, immunization of allogeneic BMT donors with a recipient-derived whole tumor cell vaccine substantially increases GVT activity but also exacerbates graft-versus-host disease.

This article has been cited by other articles:

				M.-A. Perales, A. Diab, A. D. Cohen, D. W. Huggins, J. A. Guevara-Patino, V. M. Hubbard, M. E. Engelhorn, A. A. Kochman, J. M. Eng, F. Mortazavi, et al. DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation J. Immunol., September 15, 2006; 177(6): 4159 - 4167. [Abstract] [Full Text] [PDF]

				M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF]

				M. Zoller Tumor Vaccination after Allogeneic Bone Marrow Cell Reconstitution of the Nonmyeloablatively Conditioned Tumor-Bearing Murine Host J. Immunol., December 15, 2003; 171(12): 6941 - 6953. [Abstract] [Full Text] [PDF]

				M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF]

				L. Luznik, J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll, and E. J. Fuchs Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras Blood, February 15, 2003; 101(4): 1645 - 1652. [Abstract] [Full Text] [PDF]

				T. Teshima, C. Liu, K. P. Lowler, G. Dranoff, and J. L. M. Ferrara Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation Cancer Res., February 1, 2002; 62(3): 796 - 800. [Abstract] [Full Text] [PDF]

				J. Wang, J. L. Shaw, and C. A. Mullen Down-Regulation of Antihost Alloreactivity after Bone Marrow Transplant Permits Relapse of Hematological Malignancy Cancer Res., January 1, 2002; 62(1): 208 - 212. [Abstract] [Full Text] [PDF]

				T. Teshima, N. Mach, G. R. Hill, L. Pan, S. Gillessen, G. Dranoff, and J. L. M. Ferrara Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation Cancer Res., January 1, 2001; 61(1): 162 - 171. [Abstract] [Full Text]

				L. D. Anderson Jr., S. Mori, S. Mann, C. A. Savary, and C. A. Mullen Pretransplant Tumor Antigen-specific Immunization of Allogeneic Bone Marrow Transplant Donors Enhances Graft-versus-Tumor Activity without Exacerbation of Graft-versus-Host Disease Cancer Res., October 1, 2000; 60(20): 5797 - 5802. [Abstract] [Full Text]

				L. D. Anderson Jr., C. A. Savary, and C. A. Mullen Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease Blood, April 1, 2000; 95(7): 2426 - 2433. [Abstract] [Full Text] [PDF]

				N. C. Gorin, E. Estey, R. J. Jones, H. I. Levitsky, I. Borrello, and S. Slavin New Developments in the Therapy of Acute Myelocytic Leukemia Hematology, January 1, 2000; 2000(1): 69 - 89. [Abstract] [Full Text] [PDF]